Literature DB >> 17531178

Tumoral calcinosis: new insights for the rheumatologist into a familial crystal deposition disease.

Eli Sprecher1.   

Abstract

A growing body of evidence points to extraosseous calcification (calcification occurring in nonosseous tissues) as a major cause of morbidity and mortality in humans. The term familial tumoral calcinosis encompasses a number of rare recessive diseases, often associated with increased reabsorption of phosphate through the renal proximal tubule, which manifests with periarticular or acral calcium deposition. Recently, the molecular pathogenesis of this group of disorders has been elucidated, leading to the identification of several proteins playing pivotal roles in the regulation of extraosseous calcification. This report reviews these advances as well as the potential implications of these discoveries for the management of acquired conditions associated with abnormal calcification.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531178     DOI: 10.1007/s11926-007-0038-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.686


  54 in total

1.  Tumoral calcinosis: a look into the metabolic mirror of phosphate homeostasis.

Authors:  Suzanne M Jan de Beur
Journal:  J Clin Endocrinol Metab       Date:  2005-04       Impact factor: 5.958

2.  Absence of intraepidermal glycosyltransferase ppGalNac-T3 expression in familial tumoral calcinosis.

Authors:  Orit Topaz; Reuven Bergman; Ulla Mandel; Gila Maor; Ruth Goldberg; Gabriele Richard; Eli Sprecher
Journal:  Am J Dermatopathol       Date:  2005-06       Impact factor: 1.533

Review 3.  Calcium deposition and associated chronic diseases (atherosclerosis, diffuse idiopathic skeletal hyperostosis, and others).

Authors:  Fabiola Atzeni; Piercarlo Sarzi-Puttini; Maorizio Bevilacqua
Journal:  Rheum Dis Clin North Am       Date:  2006-05       Impact factor: 2.670

Review 4.  Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortality.

Authors:  Claus Peter Schmitt; Tobias Odenwald; Eberhard Ritz
Journal:  J Am Soc Nephrol       Date:  2006-04       Impact factor: 10.121

5.  A deleterious mutation in SAMD9 causes normophosphatemic familial tumoral calcinosis.

Authors:  Orit Topaz; Margarita Indelman; Ilana Chefetz; Dan Geiger; Aryeh Metzker; Yoram Altschuler; Mordechai Choder; Dani Bercovich; Jouni Uitto; Reuven Bergman; Gabriele Richard; Eli Sprecher
Journal:  Am J Hum Genet       Date:  2006-08-24       Impact factor: 11.025

6.  Osteomas of the skin revisited: a clinicopathologic review of 74 cases.

Authors:  Phillip A Conlin; Laura P Jimenez-Quintero; Ronald P Rapini
Journal:  Am J Dermatopathol       Date:  2002-12       Impact factor: 1.533

7.  New insight into calcinosis of juvenile dermatomyositis: a study of composition and treatment.

Authors:  M Mukamel; G Horev; M Mimouni
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

8.  Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline.

Authors:  L P Robertson; R W Marshall; P Hickling
Journal:  Ann Rheum Dis       Date:  2003-03       Impact factor: 19.103

9.  Tumoral calcinosis--an unrecognized disease.

Authors:  S McClatchie; A D Bremner
Journal:  Br Med J       Date:  1969-01-18

10.  The syndrome of hyperostosis and hyperphosphatemia.

Authors:  M A Mikati; R E Melhem; S S Najjar
Journal:  J Pediatr       Date:  1981-12       Impact factor: 4.406

View more
  4 in total

1.  Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification.

Authors:  Eli Sprecher
Journal:  J Invest Dermatol       Date:  2009-10-29       Impact factor: 8.551

2.  Normophosphatemic familial tumoral calcinosis is caused by deleterious mutations in SAMD9, encoding a TNF-alpha responsive protein.

Authors:  Ilana Chefetz; Danny Ben Amitai; Sarah Browning; Karl Skorecki; Noam Adir; Mark G Thomas; Larissa Kogleck; Orit Topaz; Margarita Indelman; Jouni Uitto; Gabriele Richard; Neil Bradman; Eli Sprecher
Journal:  J Invest Dermatol       Date:  2007-12-20       Impact factor: 8.551

3.  GALNT3, a gene associated with hyperphosphatemic familial tumoral calcinosis, is transcriptionally regulated by extracellular phosphate and modulates matrix metalloproteinase activity.

Authors:  Ilana Chefetz; Kimitoshi Kohno; Hiroto Izumi; Jouni Uitto; Gabriele Richard; Eli Sprecher
Journal:  Biochim Biophys Acta       Date:  2008-10-11

4.  Identification of two novel mutations in the GALNT3 gene in a Chinese family with hyperphosphatemic familial tumoral calcinosis.

Authors:  Lihao Sun; Lin Zhao; Lianjun Du; Peipei Zhang; Minjia Zhang; Min Li; Tingting Liu; Lei Ye; Bei Tao; Hongyan Zhao; Jianmin Liu; Xiaoyi Ding
Journal:  Bone Res       Date:  2016-11-08       Impact factor: 13.567

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.